Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GNTA 
Genenta Science SpA ADR (GNTA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: GNTA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $22.97
1 Year Target Price $22.97
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -32.04% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 53.96M USD | Price to earnings Ratio - | 1Y Target Price 22.97 |
Price to earnings Ratio - | 1Y Target Price 22.97 | ||
Volume (30-day avg) 1 | Beta 0.62 | 52 Weeks Range 2.56 - 7.28 | Updated Date 09/14/2025 |
52 Weeks Range 2.56 - 7.28 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.57 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -32.84% | Return on Equity (TTM) -54.13% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 39100653 | Price to Sales(TTM) - |
Enterprise Value 39100653 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -11.48 | Shares Outstanding 18289900 | Shares Floating 11223393 |
Shares Outstanding 18289900 | Shares Floating 11223393 | ||
Percent Insiders 39.15 | Percent Institutions 10.74 |
Upturn AI SWOT
Genenta Science SpA ADR
Company Overview
History and Background
Genenta Science S.p.A. is a clinical-stage biotechnology company founded in 2014. It is focused on developing hematopoietic stem progenitor cell (HSPC) gene therapy for the treatment of cancer. It has developed platforms based on retroviral vectors and gene transfer technologies.
Core Business Areas
- HSPC Gene Therapy: Development of autologous HSPC gene therapy for cancer treatment. Their lead product candidate is Temferon, a genetically modified autologous hematopoietic stem progenitor cell therapy.
Leadership and Structure
The leadership team includes Pierluigi Paracchi (CEO), Carlo Alberto Castellano (CMO), and Bernhard Gentner (CSO). The company operates with a scientific advisory board to guide the development of its platform and product candidates.
Top Products and Market Share
Key Offerings
- Temferon: Temferon is Genenta Science's lead product candidate, an autologous cell therapy that involves genetically modifying a patient's own bone marrow stem cells to express the anti-tumor protein interferon-alpha (IFN-u03b1) at the site of the tumor. It's aimed at glioblastoma multiforme (GBM) and other solid tumors. Currently in clinical trials (Phase 1/2a). Market share is currently 0% as it is not yet approved. Competitors include pharmaceutical companies developing other treatments for GBM such as Roche (AVASTIN) and Novocure (Optune).
Market Dynamics
Industry Overview
The cell and gene therapy market is experiencing rapid growth, driven by advances in biotechnology and the increasing prevalence of cancer. The market is characterized by high R&D investments, regulatory hurdles, and strong unmet medical needs. There is growing interest and competition in the space.
Positioning
Genenta Science is positioned as an innovative biotechnology company focused on developing a novel cell and gene therapy approach for cancer. They are a relatively small player compared to established pharmaceutical companies, but have a potentially disruptive technology.
Total Addressable Market (TAM)
The global cell and gene therapy market is projected to reach hundreds of billions of USD in the coming years. Genenta's positioning in cancer therapy provides a large TAM, specifically targeting unmet needs in solid tumors like GBM. The company's success depends on clinical trial outcomes and regulatory approvals to capture a significant share.
Upturn SWOT Analysis
Strengths
- Novel technology platform in cell and gene therapy
- Focus on unmet medical needs in oncology
- Strong scientific team and collaborations
- Proprietary lentiviral vector platform
- Potential for durable responses in cancer patients
Weaknesses
- Early-stage clinical development
- Limited financial resources compared to larger pharmaceutical companies
- High regulatory hurdles for cell and gene therapies
- Reliance on successful clinical trial outcomes
- Market adoption challenges for novel therapies
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Positive clinical trial data leading to regulatory approval
- Increasing investment in cell and gene therapy
- Potential for breakthrough therapy designation
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from established therapies
- Manufacturing challenges for cell and gene therapies
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- Roche (RHHBY)
- Novocure (NVCR)
- Bristol Myers Squibb (BMY)
Competitive Landscape
Genenta Science operates in a competitive landscape with both established pharmaceutical companies and other biotechnology firms. Its competitive advantage lies in its novel HSPC gene therapy approach, but it faces challenges related to clinical development and regulatory approval.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by advancement of clinical trials and expansion of its R&D pipeline.
Future Projections: Future growth is contingent upon successful clinical trial outcomes and potential regulatory approvals. Analysts project significant revenue growth upon commercialization of Temferon, but timelines are uncertain.
Recent Initiatives: Recent initiatives include advancing Phase 1/2a clinical trials for Temferon in GBM and other solid tumors, and strengthening collaborations with research institutions.
Summary
Genenta Science is an early-stage biotech company with a promising gene therapy platform targeting cancer. It faces significant risks related to clinical development and regulatory approval but has the potential for high growth if Temferon proves successful. Financial health relies on continued funding through equity offerings. The company needs to show positive results in upcoming clinical trials. Its small size and novel approach present both opportunities and challenges compared to larger competitors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market estimates are subject to change. The AI-based rating is based on publicly available information and should not be the sole basis for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Genenta Science SpA ADR
Exchange NASDAQ | Headquaters Milan, MI, Italy | ||
IPO Launch date 2021-12-15 | Co-Founder, Chairman, CEO & GM Mr. Pierluigi Paracchi | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.genenta.com |
Full time employees 13 | Website https://www.genenta.com | ||
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. The company was incorporated in 2014 and is headquartered in Milan, Italy.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.